NZ602579A - Mitochondrially delivered anti-cancer compounds - Google Patents
Mitochondrially delivered anti-cancer compoundsInfo
- Publication number
- NZ602579A NZ602579A NZ602579A NZ60257909A NZ602579A NZ 602579 A NZ602579 A NZ 602579A NZ 602579 A NZ602579 A NZ 602579A NZ 60257909 A NZ60257909 A NZ 60257909A NZ 602579 A NZ602579 A NZ 602579A
- Authority
- NZ
- New Zealand
- Prior art keywords
- cancerous cell
- pro
- domain
- moiety
- oxidant
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
- C07F9/65522—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
- C07D311/72—3,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2008901261A AU2008901261A0 (en) | 2008-03-14 | Mitochondrially Delivered Anti-Cancer Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ602579A true NZ602579A (en) | 2013-12-20 |
Family
ID=41064682
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ602579A NZ602579A (en) | 2008-03-14 | 2009-03-16 | Mitochondrially delivered anti-cancer compounds |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8598145B2 (enExample) |
| EP (1) | EP2265623B1 (enExample) |
| JP (1) | JP5616798B2 (enExample) |
| KR (1) | KR101642157B1 (enExample) |
| CA (1) | CA2734208C (enExample) |
| NZ (1) | NZ602579A (enExample) |
| WO (1) | WO2009111846A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2696756A4 (en) * | 2011-04-14 | 2014-11-05 | Exalenz Bioscience Ltd | METHODS FOR THE DIAGNOSIS, PROGNOSIS, MONITORING AND TREATMENT OF HEPATOCELULAR CARCINOMA |
| WO2012174287A1 (en) * | 2011-06-15 | 2012-12-20 | The Board Of Regents Of The University Of Texas System | Luminescent nanoparticle compositions |
| HK1200459A1 (en) | 2011-09-19 | 2015-08-07 | Gencia Corporation | Modified creatine compounds |
| US9220706B2 (en) | 2012-06-01 | 2015-12-29 | National Institutes Of Health (Nih) | Inhibition of leukemic stem cells by PP2A activating agents |
| JP6375091B2 (ja) * | 2013-04-24 | 2018-08-15 | ノイジル、ジリ | 腫瘍性疾患であって特に高ｈｅｒ２タンパク質レベルの腫瘍性疾患を治療するためのタモキシフェン誘導体 |
| US10953110B2 (en) | 2014-04-25 | 2021-03-23 | Board Of Regents, The University Of Texas System | Dual emissive metal nanoparticles as ratiometric pH indicators |
| WO2016144637A1 (en) * | 2015-03-06 | 2016-09-15 | The Children's Hospital Of Philadelphia | Tocopheryloxyacetate ester-based co-drug conjugates |
| CZ307146B6 (cs) * | 2015-03-31 | 2018-02-07 | Kkcg Se | Trifenylfosfoniové analogy biguanidu, způsob jejich přípravy a jejich použití jako léčiva |
| CA3004059A1 (en) | 2015-11-04 | 2017-05-11 | Prescient Pharma Llc | Anti-aging compositions and methods for using same |
| KR102361131B1 (ko) * | 2020-02-25 | 2022-02-10 | 경희대학교 산학협력단 | 항생제 내성 균주에 대해 항균활성을 갖는 항균용 조성물 |
| US20230372529A1 (en) * | 2020-10-22 | 2023-11-23 | Paean Biotechnology Inc. | Mitochondria comprising anticancer drug and use thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6331532B1 (en) * | 1998-11-25 | 2001-12-18 | University Of Otago | Mitochondrially targeted antioxidants |
| US20030069208A1 (en) | 1997-11-25 | 2003-04-10 | University Of Otago | Mitochondrially targeted antioxidants |
| WO2005019233A1 (en) | 2003-08-22 | 2005-03-03 | Antipodean Pharmaceuticals, Inc. | Mitoquinone derivatives used as mitochondrially targeted antioxidants |
| CA2399802C (en) | 2000-02-11 | 2009-12-08 | Research Development Foundation | Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof |
| AUPQ605800A0 (en) * | 2000-03-06 | 2000-03-30 | Silverbrook Research Pty Ltd | Printehead assembly |
| WO2002093063A1 (en) * | 2001-05-17 | 2002-11-21 | Imperial College Innovations Limited | Production and processing plant with a rigid pipe portion curving in three dimensions |
| AU2005269383A1 (en) | 2004-07-28 | 2006-02-09 | Sd Pharmaceuticals, Inc. | Stable injectable composition of alpha tocopheryl succinate, analogues and salts thereof |
| KR100556527B1 (ko) * | 2004-11-04 | 2006-03-06 | 삼성전자주식회사 | 트렌치 소자 분리막 형성 방법 및 불휘발성 메모리 장치의제조 방법 |
| WO2006094203A1 (en) * | 2005-03-02 | 2006-09-08 | Northeastern University | Mitochondriotropic phospholipid vesicles |
| RU2318500C2 (ru) | 2005-10-18 | 2008-03-10 | Общество С Ограниченной Ответственностью "Митотехнология" | Способ воздействия на организм путем адресной доставки биологически активных веществ в митохондрии, фармацевтическая композиция для его осуществления и соединение, применяемое для этой цели |
| US8410056B2 (en) | 2006-09-15 | 2013-04-02 | Stephen John Ralph | Pro-oxidant anti-cancer compounds |
| JP4930026B2 (ja) * | 2006-12-13 | 2012-05-09 | 富士ゼロックス株式会社 | 積層体、無端状ベルト、定着装置及び画像形成装置 |
| DE102007025423A1 (de) * | 2007-05-30 | 2008-12-04 | Friedrich-Schiller-Universität Jena | Triphenylphosphonium-Derivate zum gezielten Transport und Freisetzen von Substanzen in Mitochondrien sowie Verfahren zu deren Verwendung |
-
2009
- 2009-03-16 CA CA2734208A patent/CA2734208C/en active Active
- 2009-03-16 US US12/922,525 patent/US8598145B2/en not_active Ceased
- 2009-03-16 NZ NZ602579A patent/NZ602579A/en not_active IP Right Cessation
- 2009-03-16 EP EP09720005.9A patent/EP2265623B1/en active Active
- 2009-03-16 WO PCT/AU2009/000312 patent/WO2009111846A1/en not_active Ceased
- 2009-03-16 US US14/955,297 patent/USRE47300E1/en not_active Expired - Fee Related
- 2009-03-16 KR KR1020107022874A patent/KR101642157B1/ko active Active
- 2009-03-16 JP JP2010550000A patent/JP5616798B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| USRE47300E1 (en) | 2019-03-19 |
| US20110105437A1 (en) | 2011-05-05 |
| JP5616798B2 (ja) | 2014-10-29 |
| EP2265623A1 (en) | 2010-12-29 |
| CA2734208C (en) | 2018-01-09 |
| KR20100135803A (ko) | 2010-12-27 |
| JP2011513437A (ja) | 2011-04-28 |
| KR101642157B1 (ko) | 2016-07-22 |
| CA2734208A1 (en) | 2009-09-17 |
| WO2009111846A4 (en) | 2009-11-05 |
| EP2265623B1 (en) | 2016-07-13 |
| AU2009225261A1 (en) | 2009-09-17 |
| WO2009111846A1 (en) | 2009-09-17 |
| US8598145B2 (en) | 2013-12-03 |
| EP2265623A4 (en) | 2014-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ602579A (en) | Mitochondrially delivered anti-cancer compounds | |
| BR112013002631A2 (pt) | preparações cosméticas | |
| GB2433070A (en) | Porphyrin derivatives and their use in photon activation therapy | |
| MX2009009537A (es) | Nanoparticula que comprende rapamicina y albumina como agente anticancer. | |
| MX2013011086A (es) | (aralquilamino y heteroarilalquilamino alfa-sustituidos)pirimidini lo y 1,3,5-triazinilbenzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para su uso en el tratamiento de enfermedades proliferativas. | |
| CO6390066A2 (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
| EP1430061A4 (en) | INCLUSION COMPOUND CONTAINING CUCURBITURIL DERIVATIVES AS RECEPTOR MOLECULE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | |
| AR088622A1 (es) | 18-METIL-6,7-METILEN-3-OXO-17-PREGN-4-EN-21,17b-CARBOLACTONA, PREPARADOS FARMACEUTICOS QUE CONTIENEN LOS COMPUESTOS MENCIONADOS Y SU USO EN LA TERAPIA DE LA ENDOMETRIOSIS | |
| WO2005044181A3 (en) | Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors | |
| JO2848B1 (en) | Organic compounds | |
| CL2007001648A1 (es) | Compuesto derivado de leptomicina; conjugado que comprende agente de unión a células unido a uno o mas de dichos derivados; composiciones farmacéuticas que comprenden dicho derivado o conjugado; util en el tratamiento del cancer; proceso de preparacion de un compuesto o de un conjugado de un derivado de leptomicina. | |
| WO2010111406A3 (en) | Purine derivatives useful as anti - cancer agents | |
| NO20080442L (no) | Fosforamidat alkylator promedikament | |
| BR112013031039A2 (pt) | hidrazino 1h-imidazoquinolina-4-aminas e conjugados feitos disso | |
| BR112014002670A2 (pt) | uso de monoésteres de isossorbida como compostos antimicrobianamente ativos | |
| BR112012009250A2 (pt) | composição compreendendo conjugado anti-cd56-maitansinoide e uso da mesma | |
| MX2010007502A (es) | Compuestos de tienopiridazina, sus preparaciones, composiciones farmaceuticas y sus usos. | |
| NI201200168A (es) | Formulaciones farmacéuticas | |
| MX2010013682A (es) | Derivados de 2,4-diamino-l,3,5-triazina triciclicos utiles para el tratamiento del cancer y trastornos mieloproliferativos. | |
| CR11362A (es) | Bisfosfonatos de alquilo de 2 a 5 atomos de carbono-imidazol | |
| UY32644A (es) | Compuesto anticancerígeno y composición farmacéutica que lo contiene | |
| UA107455C2 (uk) | Похідні індолу як протиракові агенти | |
| BR112014002594A2 (pt) | uso de diésteres de isossorbida como espessantes | |
| WO2010151074A3 (ko) | 양자점-클로린 유도체의 접합체를 함유하는 광감작제 및 이를 포함하는 광역학 치료에 사용하기 위한 암 치료 및 진단용 조성물 | |
| NZ603261A (en) | Anticancer steroidal lactones unsaturated in position 7 (8) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 16 MAR 2016 BY CULLENS Effective date: 20150121 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAR 2017 BY CULLENS PTY LTD Effective date: 20160316 |
|
| ASS | Change of ownership |
Owner name: CANCURE LIMITED, AU Effective date: 20160728 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAR 2018 BY CULLENS PTY LTD Effective date: 20170223 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAR 2019 BY CULLENS PTY LTD Effective date: 20180227 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAR 2020 BY DR. STEFFEN SCHWARZ IPRIS AG Effective date: 20190312 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAR 2021 BY DR. STEFFEN SCHWARZ Effective date: 20200310 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAR 2022 BY BIRGIT KNAACK Effective date: 20210304 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAR 2023 BY BIRGIT KNAACK Effective date: 20220304 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAR 2024 BY PAVIS PAYMENTS GMBH Effective date: 20230302 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAR 2025 BY BIRGIT KNAACK Effective date: 20240229 |
|
| LAPS | Patent lapsed |